EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data

Insulinresistenz und schlechtere Behandlungsergebnisse bei Depression: Evidenz aus Primärversorgungsdaten der UK Biobank

Giuseppe Fanelli iD, Janita Bralten, Barbara Franke, Nina Roth Mota, Anna Rita Atti, Diana De Ronchi, Alessio Maria Monteleone iD, Luigi Grassi, MNESYS – Mood and Psychosis Sub-Project (Spoke 5), Alessandro Serretti iD, Chiara Fabbri iD

The British Journal of Psychiatry · 2026-07 · 229 (1) · 26-35

DOI: 10.1192/bjp.2025.82 ↗

Auf einen Blick

Bei MDD waren insulinresistenzbezogene Erkrankungen mit mehr Antidepressiva-Verordnungen, längerer Behandlungsdauer und Non-Response/Resistenz verbunden. Polygenic Scores zeigten keine Assoziation mit Behandlungsergebnissen.

Fragestellung

Besteht bei MDD ein Zusammenhang von insulinresistenzbezogenen Erkrankungen und Polygenic Scores mit dem klinischen Profil und den Behandlungsergebnissen?

Methode

Auswertung von UK-Biobank-Primärversorgungsdaten zu MDD-Fällen, insulinresistenzbezogenen Erkrankungen und Behandlungsoutcomes; Univariable Analysen und multiple Regressionen mit Adjustierung für Confounder.

Ergebnisse

Unter 30 919 MDD-Fällen waren 51,95 % IR+. Diese hatten mehr Antidepressiva-Verordnungen und längere Behandlungsdauer (P < 0,001). Nach Adjustierung waren insulinresistenzbezogene Erkrankungen mit Non-Response/Resistenz und längerer Dauer assoziiert.

Schlussfolgerung der Autor:innen

Die Ergebnisse stützen einen integrierten Behandlungsansatz, der psychiatrische und metabolische Gesundheit gemeinsam berücksichtigt, sowie frühe Intervention und Prävention von Insulinresistenz bei MDD.

Kernaussagen

  • IR+ bei MDD mit mehr Antidepressiva und längerer Behandlung
  • Insulinresistenzbezogene Erkrankungen mit Non-Response/Resistenz assoziiert
  • Keine signifikanten Zusammenhänge der PGS mit Behandlungsergebnissen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift The British Journal of Psychiatry, online erschienen am 23.06.2025. Verfasst von Giuseppe Fanelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Major Depressive Disorder, Insulin Resistance, Antidepressive Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major depressive disorder (MDD) and insulin resistance-related conditions are major contributors to global disability. Their co-occurrence complicates clinical outcomes, increasing mortality and symptom severity.

Aims

In this study, we investigated the association of insulin resistance-related conditions and related polygenic scores (PGSs) with MDD clinical profile and treatment outcomes, using primary care records from UK Biobank.

Method

We identified MDD cases and insulin resistance-related conditions, as well as measures of depression treatment outcomes (e.g. resistance) from the records. Clinical-demographic variables were derived from self-reports, and insulin resistance-related PGSs were calculated using PRS-CS. Univariable analyses were conducted to compare sociodemographic and clinical variables of MDD cases with (IR+) and without (IR−) lifetime insulin resistance-related conditions. Multiple regressions were performed to identify factors, including insulin resistance-related PGSs, potentially associated with treatment outcomes, adjusting for confounders.

Results

Among 30 919 MDD cases, 51.95% were IR+. These had more antidepressant prescriptions and classes utilisation and longer treatment duration than patients without insulin resistance-related conditions ( P < 0.001). IR+ participants showed distinctive depressive profiles, characterised by concentration issues, loneliness and inadequacy feelings, which varied according to the timing of MDD diagnosis relative to insulin resistance-related conditions. After adjusting for confounders, insulin resistance-related conditions (i.e. cardiovascular diseases, hypertension, non-alcoholic fatty liver disease, obesity/overweight, prediabetes and type 2 diabetes mellitus) were associated with antidepressant non-response/resistance and longer treatment duration, particularly when MDD preceded insulin resistance-related conditions. No significant PGS associations were found with antidepressant treatment outcomes.

Conclusions

Our findings support an integrated treatment approach, prioritising both psychiatric and metabolic health, and public health strategies aimed at early intervention and prevention of insulin resistance in MDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderInsulin ResistanceAntidepressive AgentsHumansFemaleMaleUnited KingdomMiddle AgedPrimary Health CareTreatment OutcomeAgedUK BiobankComorbidityAdult

Stichwörter der Autor:innen

Treatment-resistant depression (TRD)coronary artery disease (CAD)electronic health care records (EHR)multimorbidityselective serotonin reuptake inhibitors (SSRI)

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Psychiatry, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.

ORCID-Profile: Giuseppe Fanelli, Alessio Maria Monteleone, Alessandro Serretti, Chiara Fabbri

Zitieren

APA

Fanelli, G., Bralten, J., Franke, B., Roth Mota, N., Atti, A. R., De Ronchi, D., Monteleone, A. M., Grassi, L., MNESYS – Mood and Psychosis Sub-Project (Spoke 5), Serretti, A., & Fabbri, C. (2026). Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data. The British Journal of Psychiatry, 229(1), 26-35. https://doi.org/10.1192/bjp.2025.82

Vancouver

Fanelli G, Bralten J, Franke B, Roth Mota N, Atti AR, De Ronchi D, et al. Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data. The British Journal of Psychiatry. 2026;229(1):26-35. doi:10.1192/bjp.2025.82

BibTeX
@article{Fanelli2026,
  author = {Fanelli, Giuseppe and Bralten, Janita and Franke, Barbara and Roth Mota, Nina and Atti, Anna Rita and De Ronchi, Diana and Monteleone, Alessio Maria and Grassi, Luigi and MNESYS – Mood and Psychosis Sub-Project (Spoke 5), MNESYS – Mood and Psychosis Sub-Project (Spoke 5) and Serretti, Alessandro and Fabbri, Chiara},
  title = {Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data},
  journal = {The British Journal of Psychiatry},
  year = {2026},
  volume = {229},
  number = {1},
  pages = {26--35},
  doi = {10.1192/bjp.2025.82}
}
Kostenlos starten →